We are committed to serving the best interests of our shareholders.

PRESS RELEASES

Date Title and Summary Additional Formats
Toggle Summary TESARO Announces Third-Quarter 2013 Operating Results
Top-Line Results Expected to be Announced at Year-End 2013 from Two Phase 3 Trials of Oral Rolapitant Patient Enrollment in the Third Phase 3 Trial of Oral Rolapitant Expected to Conclude at Year End; Top-Line Results Now Anticipated in Early 2014 Dose Ranging Study of Intravenous Rolapitant
View HTML
Toggle Summary TESARO to Announce Third Quarter 2013 Financial Results on November 7, 2013
WALTHAM, Mass., Oct. 24, 2013 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO) will announce its third quarter 2013 financial results on Thursday, November 7, 2013, after the close of the U.S. financial markets. TESARO's senior management will host a conference call and live audio webcast on
View HTML
Toggle Summary TESARO Announces Initiation of Rolapitant IV Clinical Program
WALTHAM, Mass., Sept. 30, 2013 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO), an oncology-focused biopharmaceutical company, today announced that an open label, dose-finding and escalation study has been initiated to evaluate the pharmacokinetics, safety and tolerability of an intravenous (IV)
View HTML
Toggle Summary TESARO Describes Initial Phase 1 Clinical Data for TSR-011 Presented at the European Cancer Congress 2013
TSR-011 Identified as a Potent Dual Inhibitor of ALK and TRK Kinases Preliminary Clinical Activity Demonstrated in Patients with Several Tumors, Including ALK-Positive NSCLC Patients Previously Treated with Crizotinib Phase 2 Dose Selection and Cohort Expansion Into Patients With ALK-Positive or
View HTML
Toggle Summary TESARO to Participate in Several Upcoming Investor Conferences
WALTHAM, Mass., Aug. 30, 2013 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO), an oncology-focused biopharmaceutical company, announced that Lonnie Moulder, CEO of TESARO, and Mary Lynne Hedley, Ph.D., President of TESARO, will participate in several upcoming investor conferences during the month of
View HTML
Toggle Summary TESARO Announces Second-Quarter 2013 Operating Results
Top-Line Results from Rolapitant Phase 3 Program to be Announced by Year-End 2013 Patient Enrollment Ongoing in Phase 3 Trial of Niraparib in Ovarian Cancer Phase 3 Trial of Niraparib in Breast Cancer On Track to Begin 2H 2013 First TSR-011 Clinical Data Accepted for Presentation at ESMO Cash and
View HTML
Toggle Summary TESARO Initiates Phase 3 Trial of Niraparib for Treatment of Patients With Ovarian Cancer
First Patient Enrolled in the NOVA Study
View HTML
Toggle Summary TESARO to Announce Second Quarter 2013 Financial Results on July 25, 2013
WALTHAM, Mass., July 18, 2013 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO) will announce its second quarter 2013 financial results on Thursday, July 25, 2013, after the close of the U.S. financial markets. TESARO's senior management will host a conference call and live audio webcast on Thursday,
View HTML
Toggle Summary TESARO to Present at the 8th Annual JMP Securities Healthcare Conference
WALTHAM, Mass., July 2, 2013 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO) announced today that Lonnie Moulder, Chief Executive Officer, will present at the 8 th Annual JMP Securities 2013 Healthcare Conference at The St. Regis Hotel in New York City on Tuesday, July 9, 2013 at 1:30 p.m. EDT.
View HTML
Toggle Summary TESARO Announces Presentation of Rolapitant Pharmacokinetic (PK) Data at the MASCC/ISOO International Symposium
PK Data from Drug-Drug Interaction Study Describes Lack of CYP3A4 Interactions BERLIN, June 28, 2013 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO), an oncology-focused biopharmaceutical company, today announced that results from a pharmacokinetic study of rolapitant, an NK-1 receptor antagonist,
View HTML